Trial Profile
A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TIES
- 01 May 2019 Status changed from completed to active, no longer recruiting.
- 01 May 2019 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 01 May 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.